advanced search

<< Back To Home

CSU 136/2011: BENEFITS AND COSTS OF PNEUMO AND ROTA VACCINE IN UGANDA

Saturday, 16th of April 2011

 

Forthcoming in Vaccine. Abstract only; full text available to subscribers.

Good reading.

BD

Projected health benefits and costs of pneumococcal and rotavirus vaccination in Uganda

 

References and further reading may be available for this article. To view references and further reading you must purchase this article.

Jacqueline E. Tate^{a, ,} , Annet Kisakye^b, Prosper Mugyenyi^c, Diana Kizza^d, Amos Odiit^e and Fiona Braka^f

^a Centers for Disease Control and Prevention, 1600 Clifton Rd. NE, MS-A47, Atlanta, GA 30333, USA

^b World Health Organization Country Office Uganda, Uganda

^c Ministry of Health/Uganda National Expanded Programme on Immunization, Kampala, Uganda

^d Sabin Vaccine Institute, Kampala, Uganda

^e Mulago National Referral Hospital, Kampala, Uganda

^f World Health Organization Country Office Ethiopia, Ethiopia

 

Abstract

We determined impact and cost-effectiveness of pneumococcal and rotavirus vaccination programs among children < 5 years of age in Uganda from the public health system perspective. Disease-specific models compared the disease burden and cost with and without a vaccination program. If introduced, pneumococcal and rotavirus vaccine programs will save 10,796 and 5265 lives, respectively, prevent 94,071 Streptococcus pneumoniae and 94,729 rotavirus cases in children < 5 years, and save 3886 and 996 million Ugandan shillings ($2.3 and $0.6 million US dollars), respectively, in direct medical costs annually. At the GAVI price ($0.15/dose), pneumococcal vaccine will be cost-saving and rotavirus vaccine highly cost-effective.